These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38036059)

  • 1. Effects of Beta Lactams on Behavioral Outcomes of Substance Use Disorders: A Meta-Analysis of Preclinical Studies.
    Alasmari MS; Almohammed OA; Hammad AM; Altulayhi KA; Alkadi BK; Alasmari AF; Alqahtani F; Sari Y; Alasmari F
    Neuroscience; 2024 Jan; 537():58-83. PubMed ID: 38036059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-lactams modulate astroglial glutamate transporters and attenuate dependence to CP 55,940, a CB1 receptor agonist, in rat model.
    Hakami AY; Alshehri FS; Sari Y
    Behav Brain Res; 2019 Feb; 359():709-718. PubMed ID: 30257184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
    Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
    Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis.
    Duailibi MS; Cordeiro Q; Brietzke E; Ribeiro M; LaRowe S; Berk M; Trevizol AP
    Am J Addict; 2017 Oct; 26(7):660-666. PubMed ID: 28898494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deployment of personnel to military operations: impact on mental health and social functioning.
    Bøg M; Filges T; Jørgensen AMK
    Campbell Syst Rev; 2018; 14(1):1-127. PubMed ID: 37131363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of N-acetylcysteine in the management of substance use disorders.
    McClure EA; Gipson CD; Malcolm RJ; Kalivas PW; Gray KM
    CNS Drugs; 2014 Feb; 28(2):95-106. PubMed ID: 24442756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in mice.
    Alajaji M; Bowers MS; Knackstedt L; Damaj MI
    Psychopharmacology (Berl); 2013 Aug; 228(3):419-26. PubMed ID: 23503685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.
    Vardakas KZ; Voulgaris GL; Maliaros A; Samonis G; Falagas ME
    Lancet Infect Dis; 2018 Jan; 18(1):108-120. PubMed ID: 29102324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of β -caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction.
    Asth L; Cruz LC; Soyombo N; Rigo P; Moreira FA
    Curr Neuropharmacol; 2023; 21(2):213-218. PubMed ID: 36173065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Δ
    Xi ZX; Muldoon P; Wang XF; Bi GH; Damaj MI; Lichtman AH; Pertwee RG; Gardner EL
    Br J Pharmacol; 2019 Dec; 176(24):4773-4784. PubMed ID: 31454413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of dependence to cannabinoids by GLT-1 activating property of the beta-lactam antibiotic.
    Ulugol A
    Med Hypotheses; 2013 Mar; 80(3):247-8. PubMed ID: 23253111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis.
    Devoe DJ; Dimitropoulos G; Anderson A; Bahji A; Flanagan J; Soumbasis A; Patten SB; Lange T; Paslakis G
    J Eat Disord; 2021 Dec; 9(1):161. PubMed ID: 34895358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β_lactam antibiotics against drug addiction: A novel therapeutic option.
    Esmaili-Shahzade-Ali-Akbari P; Ghaderi A; Hosseini SMM; Nejat F; Saeedi-Mofrad M; Karimi-Houyeh M; Ghattan A; Etemadi A; Rasoulian E; Khezri A
    Drug Dev Res; 2023 Nov; 84(7):1411-1426. PubMed ID: 37602907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.
    Roberts-Wolfe DJ; Kalivas PW
    CNS Neurol Disord Drug Targets; 2015; 14(6):745-56. PubMed ID: 26022265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator.
    Gregg RA; Hicks C; Nayak SU; Tallarida CS; Nucero P; Smith GR; Reitz AB; Rawls SM
    Neuropharmacology; 2016 Sep; 108():111-9. PubMed ID: 27085607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis.
    Ray LA; Meredith LR; Kiluk BD; Walthers J; Carroll KM; Magill M
    JAMA Netw Open; 2020 Jun; 3(6):e208279. PubMed ID: 32558914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
    Galaj E; Xi ZX
    CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.